HLA表位错配负荷与肾移植后新生供体特异性抗体、排斥反应及移植物失败的关系:一项观察性队列研究
该单中心回顾性队列研究对926对肾移植供受者进行高分辨率HLA基因分型,用HLAMatchmaker算法计数HLA表位错配。结果显示新生供体特异性抗体(DSA)发生于43例(4.6%),抗体验证的表位错配负荷与新生DSA及移植物失败独立相关,主要源于DQ抗体验证表位的效应,且呈线性关系无安全阈值。
要点
- 抗体验证的HLA-DQ表位错配负荷与新生DSA及移植物失败独立相关,效应呈线性无安全阈值。
- 每增加一个抗体验证的DQ表位错配,T细胞介导排斥的比值比增加5%,抗体介导排斥增加12%。
- 其他位点表位错配效应较小,采用DQA1/DQB1分子配型可能减少新生DSA并改善结局。
核心结论
- HLA-DQ的表位错配显著增加肾移植后新生DSA形成、移植物排斥和移植物失败的风险。
- 其他位点的表位错配效应似乎较小。
- 抗体验证的HLA-DQ表位错配负荷可用于指导个体化移植后免疫抑制。
研究设计与样本
- 单中心观察性队列研究,纳入2004年3月至2013年2月连续成人肾移植受者。
- 对926对移植供受者进行HLA位点回顾性高分辨率基因分型。
- 使用HLAMatchmaker计算机算法计数HLA表位错配。
主要发现
- 新生DSA发生于43例(4.6%)患者。
- 多变量分析显示抗体验证的表位错配负荷与新生DSA发生及移植物失败显著独立相关,主要归因于DQ抗体验证表位的效应。
- 与DQ抗体验证表位错配的关联呈线性,无新生DSA不发生的安全阈值。
- 每增加一个抗体验证的DQ表位错配,T细胞介导排斥的比值比增加5%,抗体介导排斥的比值比增加12%。
临床怎么用
- 可考虑用抗体验证的HLA-DQ表位错配负荷指导肾移植后个体化免疫抑制方案。
- 采用DQA1和DQB1等位基因的分子配型可能有助于减少新生DSA形成并潜在改善移植结局。
局限性
- 单中心回顾性研究,外推性需谨慎。
- 仅对HLA位点进行回顾性基因分型,未提及其他潜在混杂因素的控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In kidney transplantation, evaluating mismatches of HLA eplets-small patches of surface-exposed amino acids of the HLA molecule-instead of antigen mismatches might offer a better approach to assessing donor-recipient HLA incompatibility and improve risk assessment and prediction of transplant outcomes. METHODS: To evaluate the effect of number of eplet mismatches (mismatch load) on de novo formation of donor-specific HLA antibodies (DSAs) and transplant outcomes, we conducted a cohort study that included consecutive adult kidney recipients transplanted at a single center from March 2004 to February 2013. We performed retrospective high-resolution genotyping of HLA loci of 926 transplant pairs and used the HLAMatchmaker computer algorithm to count HLA eplet mismatches. RESULTS: De novo DSAs occurred in 43 (4.6%) patients. Multivariable analysis showed a significant independent association between antibody-verified eplet mismatch load and de novo DSA occurrence and graft failure, mainly explained by DQ antibody-verified eplet effects. The association with DQ antibody-verified eplet mismatches was linear, without a safe threshold at which de novo DSA did not occur. Odds for T cell- or antibody-mediated rejection increased by 5% and 12%, respectively, per antibody-verified DQ eplet mismatch. CONCLUSIONS: Eplet mismatches in HLA-DQ confer substantial risk for de novo DSA formation, graft rejection, and graft failure after kidney transplantation. Mismatches in other loci seem to have less effect. The results suggest that antibody-verified HLA-DQ eplet mismatch load could be used to guide personalized post-transplant immunosuppression. Adoption of molecular matching for DQA1 and DQB1 alleles could also help to minimize de novo DSA formation and potentially improve transplant outcomes.
引用
- Senev A, Coemans M, Lerut E, et al. Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. J Am Soc Nephrol. 2020. PMID: 32764139. doi:10.1681/ASN.2020010019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。